Benzinga · Aug 26, 2026
JP Morgan Reinstates Overweight on Amneal Pharmaceuticals, Announces $22 Price Target
JP Morgan analyst Chris Schott reinstates Amneal Pharmaceuticals (NASDAQ:AMRX) with a Overweight and announces $22 price target.
AM
NASDAQ · AMRX
Amneal Pharmaceuticals, Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
$17.87
Down-$0.39 (-2.17%)
Updated Sep 4, 2026, 5:14 PM
SID Score
5.3/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 4.34B
- P/E ratio
- 60.06
- Dividend yield
- 0.00%
- 52-week range
- $11.71 – $19.26
- Volume
- 2.75M
- Avg. volume
- 2.49M
Price performance
AMRX price history
1M range · 21 trading sessions · Daily adjusted prices
AMRX closed at $17.87 after 21 trading sessions, down 1.11% for the selected period.
- Last close
- $17.87
- Period change
- -1.11%
- Period low
- $17.10
- Period high
- $18.42
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 3, 2026 | $18.25 | $18.26 | $17.735 | $17.87 | 2.75M |
| Sep 2, 2026 | $17.90 | $18.32 | $17.61 | $18.06 | 2.61M |
| Sep 1, 2026 | $17.57 | $17.99 | $17.40 | $17.68 | 1.36M |
| Aug 31, 2026 | $17.46 | $17.615 | $17.175 | $17.47 | 1.74M |
| Aug 28, 2026 | $18.04 | $18.10 | $17.47 | $17.54 | 1.15M |
| Aug 27, 2026 | $17.82 | $18.11 | $17.60 | $18.01 | 1.1M |
| Aug 26, 2026 | $18.00 | $18.12 | $17.85 | $17.99 | 1.21M |
| Aug 25, 2026 | $17.78 | $17.96 | $17.61 | $17.92 | 1.14M |
| Aug 24, 2026 | $17.81 | $17.92 | $17.6101 | $17.78 | 1.79M |
| Aug 21, 2026 | $17.99 | $18.12 | $17.77 | $17.91 | 1.37M |
| Aug 20, 2026 | $17.87 | $18.025 | $17.7338 | $17.90 | 1.25M |
| Aug 19, 2026 | $18.51 | $18.58 | $17.95 | $18.11 | 1.47M |
| Aug 18, 2026 | $18.45 | $18.76 | $18.02 | $18.19 | 2.03M |
| Aug 17, 2026 | $18.01 | $18.44 | $17.92 | $18.42 | 1.62M |
| Aug 14, 2026 | $17.07 | $18.17 | $16.87 | $18.15 | 2.01M |
| Aug 13, 2026 | $17.69 | $17.885 | $17.26 | $17.27 | 2.24M |
| Aug 12, 2026 | $17.10 | $17.67 | $16.77 | $17.66 | 2.93M |
| Aug 11, 2026 | $17.83 | $18.00 | $17.07 | $17.10 | 2.25M |
| Aug 10, 2026 | $18.03 | $18.195 | $17.735 | $17.88 | 1.35M |
| Aug 7, 2026 | $18.15 | $18.215 | $17.93 | $18.14 | 1.09M |
| Aug 6, 2026 | $18.70 | $18.81 | $17.93 | $18.07 | 1.4M |
Latest AMRX news
The latest Smart Investors Daily articles mentioning AMRX.
Stock researchCompany · Overview
AMRX research
Overview
Company profile and research snapshot.
Company profile
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $15.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 26, 2026 | JP Morgan | Overweight | — |
| Aug 3, 2026 | UBS | Buy | — |
| Jul 15, 2026 | UBS | Buy | — |
| May 20, 2026 | Barclays | Overweight | — |
| Apr 17, 2026 | UBS | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 14, 2026
Sell Alert: Nikita Shah Cashes Out $2.56M In Amneal Pharmaceuticals Stock
It was reported on August 13, that Nikita Shah, Executive Vice President at Amneal Pharmaceuticals (NASDAQ:AMRX) executed a significant insider sell, according to an SEC filing. What Happened: Shah's decision to
Benzinga · Aug 14, 2026
Insider Unloading: Jason Daly Sells $3.77M Worth Of Amneal Pharmaceuticals Shares
Jason Daly, EVP at Amneal Pharmaceuticals (NASDAQ:AMRX), disclosed an insider sell on August 13, according to a recent SEC filing. What Happened: Daly's decision to sell 216,613 shares of Amneal Pharmaceuticals was
Benzinga · Aug 3, 2026
UBS Maintains Buy on Amneal Pharmaceuticals, Raises Price Target to $25
UBS analyst Ashwani Verma maintains Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy and raises the price target from $23 to $25.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
